8-K: DocGo Announces Mixed Q4 Results, Full-Year 2024 Revenue Slightly Down, Focus Shifts to Core Mobile Health

DocGo reports full-year revenue of $616.6 million, a slight decrease from the previous year, and announces a shift in focus towards core mobile health services amidst the wind-down of migrant-related programs.

Summary

• DocGo announced its Q4 and full-year 2024 financial results.
• Full-year 2024 revenue was $616.6 million, slightly lower than the $624.2 million reported in 2023.
• GAAP gross margin for the full year increased to 32.1% from 28.7% in the previous year.
• Adjusted gross margin for the full year also improved to 34.6% compared to 31.3% in 2023.
• Full-year net income rose to $13.4 million from $10.0 million in 2023.
• Adjusted EBITDA for the full year was $60.3 million, up from $54.0 million in the prior year.
• Mobile Health Services revenue for the full year decreased to $423.1 million from $442.8 million in 2023.
• Transportation Services revenue increased to $193.5 million from $181.5 million in the previous year.
• Q4 2024 revenue was $120.8 million, significantly lower than the $199.2 million in Q4 2023, primarily due to the wind-down of migrant-related programs.
• The company reported a net loss of $7.6 million for Q4 2024, compared to a net income of $8.0 million in Q4 2023.
• Adjusted EBITDA for Q4 2024 was $1.1 million, a substantial decrease from $22.6 million in Q4 2023.
• As of December 31, 2024, DocGo held $107.3 million in cash and cash equivalents.
• Full-year 2025 revenue is projected to be $410-$450 million.
• Full-year 2025 adjusted EBITDA margin is now expected to be approximately 5%, down from the previous estimate of 8%-10%.

Sentiment

Score: 6

Explanation: The sentiment is mixed. While full-year results show some improvement, the Q4 performance was weaker than expected due to the wind-down of migrant programs and increased investments. The lowered EBITDA margin guidance for 2025 also contributes to a less positive outlook.

Positives

• Full-year net income increased to $13.4 million from $10.0 million in 2023.
• Adjusted gross margin for the full year improved to 34.6% compared to 31.3% in 2023.
• Transportation Services revenue increased to $193.5 million from $181.5 million in the previous year.
• DocGo surpassed 700,000 patients assigned for care gap closure programs, up from just 2,000 a little over a year ago.
• The company's Net Promoter Score (NPS) in the fourth quarter was 86 for its care gap closure programs.
• The company expects to collect approximately $150 million in migrant-related project receivables by the end of the second quarter.

Negatives

• Full-year 2024 revenue was slightly lower at $616.6 million compared to $624.2 million in 2023.
• Q4 2024 revenue was significantly lower at $120.8 million compared to $199.2 million in Q4 2023.
• The company reported a net loss of $7.6 million for Q4 2024, compared to a net income of $8.0 million in Q4 2023.
• Adjusted EBITDA for Q4 2024 was $1.1 million, a substantial decrease from $22.6 million in Q4 2023.
• Full-year 2025 adjusted EBITDA margin is now expected to be approximately 5%, down from the previous estimate of 8%-10%.

Risks

• The wind-down of migrant-related programs negatively impacted Q4 revenue and adjusted EBITDA.
• Unanticipated acceleration in the wind down of migrant programs by New York City Health and Hospitals (NYC HH) and the early closure of HPD migrant sites in Upstate NY resulted in a negative impact of approximately $9.0 million on Q4 revenue and $5.3 million on Q4 adjusted EBITDA.
• Increased investment in the payer vertical reduced fourth quarter adjusted EBITDA by approximately $1.5 million.
• Increased loss reserves for self-insured lines reduced fourth quarter adjusted EBITDA by approximately $3.2 million.
• The company's ability to successfully transition operations from migrant revenue to core mobile health revenue is a risk.
• The company's ability to expand its programs with insurance partners, hospital systems, municipalities, other government entities and other strategic partners is a risk.
• The company's ability to maintain sufficient cash balances is a risk.
• The company's reliance on government contracts is a risk.
• The company's ability to effectively manage its growth is a risk.

Future Outlook

Full-year 2025 revenue is expected to be $410-$450 million, unchanged from the previous estimate, but the full-year 2025 adjusted EBITDA margin is now expected to be approximately 5%, down from the previous estimate of 8%-10%.

Management Comments

• Lee Bienstock, Chief Executive Officer of DocGo, commented, 'We continue to experience strong demand for our care gap closure programs in our payer and provider vertical, and are investing heavily to support this growth.'
• Norm Rosenberg, Chief Financial Officer of DocGo, also commented, 'While our adjusted EBITDA came in lower than our previous expectations, that was driven in part by higher SG&A to support the growth and buildout of our payer and provider vertical, which included investments in our people, our tech stack and in quality initiatives to ensure we deliver a world-class product.'

Industry Context

DocGo's shift towards core mobile health services reflects a broader trend in the healthcare industry towards proactive and accessible care models. The company's focus on care gap closure programs aligns with the increasing emphasis on value-based care and preventative healthcare.

Comparison to Industry Standards

• DocGo's adjusted gross margin of 34.6% for the full year 2024 is comparable to other technology-enabled healthcare service providers.
• Teladoc Health, a leading telehealth company, reported a gross margin of 68.3% for the full year 2023, but operates with a different business model.
• American Medical Response (AMR), a major player in the medical transportation industry, does not publicly disclose detailed margin information, making a direct comparison difficult.
• DocGo's Net Promoter Score (NPS) of 86 for its care gap closure programs is considered 'world class' in the healthcare industry, indicating high patient satisfaction.

Stakeholder Impact

• Shareholders may be concerned about the decline in Q4 revenue and the lowered EBITDA margin guidance for 2025.
• Employees may be affected by the transition from migrant-related programs to core mobile health services.
• Customers and patients are expected to benefit from the company's focus on expanding its care gap closure programs and improving patient experience.
• Suppliers and creditors may be impacted by the company's financial performance and its ability to meet its obligations.

Next Steps

• The company intends to focus on expanding its care gap closure programs and transitioning operations from migrant revenue to core mobile health revenue.
• DocGo plans to continue investing in its tech stack to streamline patient intake and reduce booking friction.
• The company expects to collect approximately $150 million in migrant-related project receivables by the end of the second quarter.

Key Dates